Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center

7Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Purpose: The processes for formulary implementation and electronic health record (EHR) integration of biosimilar products at a comprehensive cancer center are described. Implications for research protocols are also discussed. Summary: The existing literature focuses on practical considerations for formulary addition of biosimilar products, but there is a lack of guidance on how to implement the change, particularly within the EHR. Before building the ordering tools for biosimilars, the clinical and informatics teams should determine the role of biosimilars at the institution, identify drug-specific product characteristics that affect medication build, and characterize implications of future formulary changes or drug shortages. Leveraging an orderable record provides the ability to include logic that maps to multiple products and also allows for future implementation of changes within the medication record rather than requiring "swaps"at the treatment protocol level. The institutional review board should coordinate changes in affected research protocols and consent forms and work with principal investigators to amend protocols when necessary. Pharmacy leaders should develop processes to oversee inventory during the transition period and minimize the risk of errors. Conclusion: The development of a standardized approach for evaluating and implementing biosimilar products improves efficiency and collaboration among the various team members responsible for the products' integration into existing workflows, including implications for clinical research. Implementing biosimilars for agents used to treat cancer will pose new challenges and require additional considerations. Partial implementation of biosimilars continues to pose multiple challenges in the provision of patient care.

References Powered by Scopus

American society of clinical oncology statement: Biosimilars in oncology

97Citations
N/AReaders
Get full text

Why are biosimilars not living up to their promise in the US?

60Citations
N/AReaders
Get full text

Biosimilars: Implications for health-system pharmacists

58Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System

6Citations
N/AReaders
Get full text

A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report

5Citations
N/AReaders
Get full text

An Institutional Guide for Formulary Decisions of Biosimilars

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Villanueva, M. N., Davis, J. E., & Sobocinski, S. M. (2021). Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center. American Journal of Health-System Pharmacy, 78(3), 249–260. https://doi.org/10.1093/ajhp/zxaa373

Readers over time

‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

80%

Professor / Associate Prof. 1

20%

Readers' Discipline

Tooltip

Nursing and Health Professions 3

38%

Pharmacology, Toxicology and Pharmaceut... 3

38%

Biochemistry, Genetics and Molecular Bi... 1

13%

Sports and Recreations 1

13%

Save time finding and organizing research with Mendeley

Sign up for free
0